Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same

Patent metadata

Field	Value
Publication number	US-12227478-B2
Application number	US-202017594062-A
Country	US
Kind code	B2
Filing date	Apr 3, 2020
Priority date	Apr 5, 2019
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

Provided are a process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib, an intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate, an intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, and a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof.

First claim

The invention claimed is:

1. A process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, the process of which comprises:
(a) reacting racemic methyl (1-benzyl-4-methylpiperidin-3-yl) carbamate and dibenzoyl-L-tartaric acid by heating under reflux in a solvent selected from the group consisting of isopropanol, an aqueous solution of isopropanol, and a mixed solvent of isopropanol and an organic solvent, followed by cooling to prepare isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate dibenzoyl-L-tartrate; and
(b) reacting the isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate dibenzoyl-L-tartrate prepared in Step (a) with a base to convert to methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate; reducing the methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate to prepare (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine; and then reacting the (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine with acetic acid to prepare (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate.

2. The process according to claim 1 , wherein the mixed solvent of isopropanol and an organic solvent is a mixed solvent of isopropanol and an organic solvent selected from the group consisting of methanol, ethanol, n-propanol, acetone, methylethylketone, methyl acetate, ethyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran and acetonitrile.

3. The process according to claim 1 , wherein Step (a) further comprises recrystallizing the isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate dibenzoyl-L-tartrate in a mixed solvent of isopropanol and methanol or a mixed solvent of isopropanol and ethanol.

4. The process according to claim 1 , wherein the cooling in Step (a) is performed to a temperature ranging from 0 to 55° C.

5. The process according to claim 1 , wherein the base used in Step (b) is one or more selected from the group consisting of potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, and potassium hydroxide.

6. The process according to claim 1 , wherein the reducing of Step (b) is carried out by using one or more reducing agents selected from the group consisting of lithium aluminium hydride, lithium bis (2-methoxyethoxy) aluminum hydride, and sodium hydride.

7. The process according to claim 1 , wherein the reaction of the (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine with acetic acid is carried out in a solvent selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, acetone, methylethylketone, methyl acetate, ethyl acetate, isopropyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, and a mixed solvent thereof.

8. Isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl) carbamate dibenzoyl-L-tartrate.

9. (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate.

10. A process for preparing tofacitinib or a pharmaceutically acceptable salt thereof, the process of which comprises:
(i) preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate according to the process according to claim 1 ;
(ii) reacting the (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof with 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine to prepare (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine;
(iii) performing debenzylation of the (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine to prepare (3R,4R)-(4-methylpiperidin-3-yl)-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine; and
(iv) reacting the (3R,4R)-(4-methylpiperidin-3-yl)-N-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine with ethyl cyanoacetate to prepare tofacitinib.

Assignees

• Yuhan Corp

Inventors

• Oh Sang-Ho
• Lee Doo-Byung
• Kwon Kyoung-Chan
• Kim Sang-Won
• Hwang Hyo-Ick
• Lee Kyeong-Sill
• Jo Ik-Su
• Choi Ji-Hye
• Cho Sung-Hee
• Lee Su-Young

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61K31/4418

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine · CPC title